Adding zipalertinib to standard chemotherapy significantly improved progression-free survival in first-line treatment of EGFR exon 20 lung cancer. Results were shared at the IASLC 2026 World Conference on Lung Cancer.
← News
Medicine Breakthroughs Medicine Breakthroughs Health
Zipalertinib plus chemotherapy significantly extends progression-free survival in first-line EGFR lung cancer
Zipalertinib Plus Chemo Drug combination
EGFR Exon 20 Lung Cancer Disease target
First-Line Therapy Treatment line
WCLC 2026 Presented at